Journal article
Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency
E Bouffet, V Larouche, BB Campbell, D Merico, R De Borja, M Aronson, C Durn, J Krueger, V Cabric, V Ramaswamy, N Zhukova, G Mason, R Farah, S Afzal, M Yalon, G Rechavi, V Magimairajan, MF Walsh, S Constantini, R Dvir Show all
Journal of Clinical Oncology | Published : 2016
Abstract
Purpose Recurrent glioblastoma multiforme (GBM) is incurable with current therapies. Biallelic mismatch repair deficiency (bMMRD) is a highly penetrant childhood cancer syndrome often resulting in GBM characterized by a high mutational burden. Evidence suggests that high mutation and neoantigen loads are associated with response to immune checkpoint inhibition. Patients and Methods We performed exome sequencing and neoantigen prediction on 37 bMMRD cancers and compared them with childhood and adult brain neoplasms. Neoantigen prediction bMMRD GBM was compared with responsive adult cancers from multiple tissues. Two siblings with recurrent multifocal bMMRD GBM were treated with the immune che..
View full abstractGrants
Awarded by Canadian Institute of Health Research joint Canada-Israel health research
Funding Acknowledgements
Supported by a Canadian Institute of Health Research joint Canada-Israel health research Grant No. 108188-001, by a Garron Family Cancer Center discovery grant, by BRAINchild Canada, and by a McLaughlin Center innovation grant.